Endocrine Abstracts

BackgroundPrevalence of hypogonadism has been reported as high as 50% in men with T2DM and/or obesity. ADA and AACE Guidelines recommend assessment of hypogonadism in men with T2DM and obesity.Material and methodsIn a registry of 865 men with hypogonadism, 361 men (41.7%) had T2DM. 183 received TU 1000 mg/12 weeks (T-group), 178 opted against treatment (CTRL). Changes over time between groups were compared an...

BackgroundWhile almost all studies consistently show reduction of waist circumference as a result of testosterone therapy (TTh), effects on body weight are inconsistent and may depend on treatment duration, route of administration, and adherence.Material and methodsAfter excluding men with primary hypogonadism, 476 men with functional, symptomatic hypogonadism were obese. 281 men received testosterone undecan...

BackgroundEffects of testosterone therapy (TTh) on lipid parameters are inconsistent and may depend on treatment duration, route of administration, and adherence. While in short-term studies, testosterone usually lowers HDL, long-term studies seem to increase HDL. Total cholesterol, LDL and triglycerides are either reduced by TTh, or effects are neutral.Material and methodsAfter excluding men with primary hyp...

Background: Hypogonadism is associated with cardiometabolic risk. Studies suggest that hypogonadism increases the risk of all-cause and cardiovascular mortality. While some short-term studies have been performed in men with CVD, there are no data on long-term effects of testosterone replacement therapy (TRT) in men with CVD.Methods: In a prospective, cumulative, observational registry study from a single urologist’s office, 300 men with testosterone...

Introduction: Improvements of anthropometric and metabolic parameters on long-term testosterone replacement therapy (TRT) from our registry studies have been reported in 2013 (Saad, Obes; Yassin and Doros, Clin Obes; Traish, Int J Clin Pract).Methods: Five hundred and sixty-one hypogonadal men from both registry studies were divided into age groups ≤65 (Group A, n=450) and >65 years (Group B, n=111). All men were treated with ...

Introduction: Numerous studies have reported inverse associations between testosterone and obesity as well as other components of the metabolic syndrome.Methods: From two registry studies of 561 hypogonadal mens, 46 mens with obesity grade III (BMI ≧40 kg/m2) were selected. All patients received TU injections for up to 6 years. 46 mens were followed for 2 years, 43 for 3 years, 37 for 4 years, 34 for 5 years, and 24 for 6 s. Declining n...

Introduction: Abdominal adipose tissue suppresses testosterone production by various mechanisms affecting the hypothalamic–pituitary–gonadal axis. Hypogonadism leads to further accumulation of fat mass thus creating a vicious circle. This study analysed the effects of restoring testosterone in obese hypogonadal men.Methods: Cumulative, prospective, registry study of 181 men (mean age: 59.11±6.06 years) with testosterone levels below 12.1 n...

Objectives: To investigate effects of testosterone in hypogonadal men with Crohn’s disease (CD).Design and methods: Thirteen men, aged 45–67 years were diagnosed with subnormal plasma testosterone. They received treatment with parenteral testosterone undecanoate. They also suffered from CD. The Crohn’s disease activity index (CDAI) (1) was used to assess the severity of the disease. Levels of testosterone and C-reactive protein (CRP) were ...